Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies

Piero Ruggenenti,*† Paola Bettinaglio,* Franck Pinares,* and Giuseppe Remuzzi*†
*Clinical Research Centre for Rare Diseases “Aldo e Cele Dacco,” Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy; and †Unit of Nephrology, Azienda Ospedaliera, Ospedali Riuniti, Bergamo, Italy

Despite the huge amount of studies looking for candidate genes, the ACE gene remains the unique, well-characterized locus clearly associated with pathogenesis and progression of chronic kidney disease, and with response to treatment with drugs that directly interfere with the renin angiotensin system (RAS), such as angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA). The II genotype is protective against development and progression of type I and type II nephropathy and is associated with a slower progression of nondiabetic proteinuric kidney disease. ACE inhibitors are particularly effective at the stage of normoalbuminuria or microalbuminuria in both type I and type II diabetics with the II genotype, whereas the DD genotype is associated with a better response to ARA therapy in overt nephropathy of type II diabetes and to ACE inhibitors in male patients with nondiabetic proteinuric nephropathies. The role of other RAS or non-RAS polymorphisms and their possible interactions with different ACE I/D genotypes are less clearly defined. Thus, evaluating the ACE I/D polymorphism is a reliable tool to identify patients at risk and those who may benefit the most of renoprotective therapy with ACE inhibitors or ARA. This may guide pharmacologic therapy in individual patients and help design clinical trials in progressive nephropathies. Moreover, it might help optimize prevention and intervention strategies at population levels, in particular, in countries where resources are extremely limited and 1 million patients continue to die every year of cardiovascular or renal disease.


More than one hundred years have elapsed since 1898, when Tigerstedt and Bergman at Karolinska Institute observed that injection of a crude extract of rabbit kidney raised the blood pressure (BP) in dogs (1). The extract contained a substance with long-lasting pressure effects that they named renin. Curiously, however, this seminal observation remained almost unnoticed until 1934, when Goldblatt showed that clamping of a kidney artery induced hypertension in the dog, an effect associated with the release of a vasopressor substance in the ipsilateral renal vein (2). Demonstrating an enhanced release of pressure substances from damaged kidneys into the circulation provided a reasonable pathophysiological explanation for the well-known association between kidney disease and arterial hypertension and revived the seminal intuition of Claude Bernard that an endocrine mechanism, the milieu interior, is involved in the regulation of the systemic BP. A few years later, the concept of a system specifically involved in BP control came to the light with discovery by Page and Braun-Menendez that renin is a peptidase that produces the vasconstrictor peptide angiotensin II from the precursor angiotensinogen (3). Since then, multidisciplinary research involving clinical scientists, pathologists, biochemists, physiologists, molecular biologists, and, more recently, geneticists, allowed identifying and characterizing many other components of the renin-angiotensin system (RAS), including the angiotensin-converting-enzyme (ACE), and specific receptors for the main RAS effectors, such as angiotensin II and aldosterone (4–10). Even more important, it soon became evident that RAS, in addition to controlling the systemic BP, may also have many other effects. Navar and Rosivall showed that angiotensin II enhances the tone of the postglomerular arteriole (11), which induces glomerular hypertension and increases the filtration fraction (12), hemodynamic adaptations that in the long-term may cause glomerular damage and dysfunction (13). Angiotensin II may also induce mesangial and vascular cell hypertrophy (14) and sustain chronic inflammation, ischemia, and fibrosis in proteinuric kidneys (15).

The awareness that chronic RAS activation could have a key role in widely diffused, highly invalidating and often fatal diseases, boosted research efforts aimed to better characterize the system and to guide the development of intervention strategies aimed to limit its effects on vessels and tissues. Along this line, a major contribution came from novel molecular biologic techniques that, since the early 1980s, allowed to clone the genes encoding for various components of the system, such as renin, ACE and angiotensinogen (AGT), as well as for angiotensin II receptors type 1 (AT1R) and type 2 (AT2R) DNA.
cloning allowed also to detect gene polymorphisms of several components of the RAS, which helped geneticists to better understand the complex relationships between RAS and disease. In 1990, Rigat et al. (16) first described the insertion (I)/deletion (D) polymorphism of the ACE gene, a major locus that accounts for approximately 50% of the total phenotypic variance of circulating and tissue ACE. Subjects carrying the D allele were found to have increased systemic and renal ACE levels, whereas those with the II genotype had the lowest ACE expression (17). Evidence that ACE is a limiting factor for angiotensin II synthesis, and therefore for most of the systemic and renal effects of the RAS, pushed researchers to focus a large part of genetic analyses of the RAS on the study of ACE I/D polymorphism. Thus, over the last decade, several studies converged to indicate that risk for development and progression of diabetic (18) and nondiabetic (19–21) chronic renal disease, as well as of related cardiovascular complications (22), varies with different I/D genotypes.

With the development of captopril, the ancestor of a new class of antihypertensive agents, the ACE inhibitors, developed with the specific objective of limiting uncontrolled RAS activation in renovascular disease, Ondetti et al. (23) paved the way to a series of pharmacologic studies that provided new and largely unexpected insights on the concert of RAS effects. Studies found that RAS inhibition may lower the BP in patients with ischemic kidney disease and in a large proportion of those with essential hypertension as well, including patients with low plasma renin activity (24). Moreover, with time, the area of application of RAS inhibitor therapy extended from arterial hypertension to left ventricular hypertrophy and congestive heart failure, prevention of stroke, atherosclerosis, atrial fibrillation, and prevention and treatment of chronic kidney disease. Evidence that RAS inhibitors can be effective even in patients without signs of activity of the system is a major challenge to explore the possibility that the pathophysiology of cardiovascular and renal disease(s) is somehow linked to the function of renin angiotensin axis. Better understanding of the complex interactions of the RAS with hemodynamic and metabolic abnormalities of patients with hypertension, diabetes or renal disease, as well as with genetic variants of other pathways possibly involved in target organ damage, will hopefully open novel perspective of therapy for these high-risk patients. Evaluating these interactions, however, is difficult: large and well-characterized patient populations with homogeneous genetic backgrounds and univocally defined and clinically relevant outcomes are needed to give enough power to the analyses and limit the risk of random data fluctuations. Moreover, studies must take into consideration the role of acquired and environmental factors that may vary from one experimental setting to the other and may confound data interpretation. Unfortunately, most of the studies performed so far failed to satisfy the above requirements, largely because of the too small sample size or the heterogeneity of studied populations; and this may explain why data on the role of the RAS, and in particular of the ACE gene, in human disease were often inconclusive and sometimes even conflicting between different studies.

Thus, our major task was to provide a critical overview of available evidence, trying to focus on most robust findings and, where possible, clean available information from unreliable or misleading data. We also discussed less solid data on other genetic factors that, combined with different ACE I/D genotypes, may contribute to the large interindividual variability in disease susceptibility and treatment response. Patients with diabetic and nondiabetic renal disease were treated separately to assess whether the same genetic factors may play a similar or different role in these two clinical settings. On the contrary, dissecting data on type I from those on type II diabetics was often difficult because many studies considered these patients together and only occasionally provided aggregate data in the two populations analyzed separately. We focused on papers considering microalbuminuria or macroalbuminuria, proteinuria, kidney function, and end-stage kidney disease (ESKD) as outcome variables. Relevant studies were retrieved by a literature search performed in MEDLINE (from 1996 to most recent) and EMBASE (from 1980 to most recent) by using specific key words according to considered genetic (RAS polymorphisms), disease (diabetic nephropathy, non-diabetic nephropathy) and drug categories (ACE inhibitors, angiotensin II receptor antagonism [ARA]). Randomized clinical trials were identified and selected for the meta-analysis according to the search strategy developed for the Cochrane Collaboration. Data on renal transplant patients were not considered.

**Onset and Progression**

**Diabetic Renal Disease**

A meta-analysis of 8663 type I and type II diabetics with incipient or overt nephropathy (defined, respectively, by the presence of microalbuminuria or macroalbuminuria/proteinuria, with or without renal insufficiency) and 6064 diabetic controls with no evidence of renal disease (defined as a urinary albumin excretion below the threshold for microalbuminuria) included in 47 studies published from 1994 to 2004, showed that those with the II ACE polymorphism had a 22% lower risk for nephropathy than homozygous or heterozygous carriers of the D allele (odds ratio [OR] = 0.78; 95% confidence interval [CI] = 0.69 to 0.88) (18). This analysis, however, considered together data in type II Asians and in type I and type II whites. When these subgroups were considered separately, the II genotype was associated with a remarkably lower (35%) risk in type II Asians (OR = 0.65; 95% CI = 0.51 to 0.83) but had only a marginal impact on disease onset in type I (OR = 0.83; 95% CI = 0.65 to 1.07) and type II (OR = 0.90; 95% CI = 0.78 to 1.04) whites. A closer look at the data showed that risk for microalbuminuria was only marginally associated with the ACE I/D polymorphism in each subgroup, whereas risk for macroalbuminuria was lower in patients with the II genotype, in particular in type II Asians. A possible explanation is that, unlike macroalbuminuria, microalbuminuria does not necessarily reflect structural kidney damage and may be associated with insulin resistance, endothelial dysfunction, obesity, heart failure, and other clinical conditions that may not be affected by ACE I/D polymorphism or race, and may therefore confound data interpretation by masking (i.e., “diluting”) the association, if any, between II genotype and lower risk for incipient nephropathy.

The association between ACE polymorphism and nephropa-
Although to a different extent in different considered populations, smoking and with a different incidence and progression of IgA nephropathy, is not associated with the progression of APKD but may affect both the incidence and progression of IgA nephropathy, these studies were recently reviewed in two comprehensive meta-analyses showing that this polymorphism is not associated with chronic kidney disease both in type I and type II diabetics. A possible explanation is that changes in blood glucose may affect renal hemodynamics to a different extent in different genotypes. Indeed, hyperglycemia does not appreciably affect the glomerular filtration rate (GFR) in diabetics with the II genotype and low plasma ACE levels, whereas in those with the ID and DD genotype it induces a GFR increase that correlates with ACE plasma levels (27). A plausible and intriguing explanation is that vasodilatation of the arterioles afferent to the glomeruli is NO dependent and is amplified by local angiotensin II levels in a dose-dependent manner (28). Thus, in patients with the II genotype, reduced angiotensin II bioavailability secondary to decreased ACE activity may limit glucose-induced preglomerular vasodilatation. In carriers of the I allele, this might translate into less severe hyperfiltration, in particular in those with less effective metabolic control who, in the long term, would be to some extent protected from development and progression of nephropathy (25). Data on the association between the ACE genotype and microalbuminuria are less consistent and need to be confirmed in more powerful studies.

Nondiabetic Renal Disease

The role of the ACE I/D polymorphism in nondiabetic chronic kidney disease is far from being definitively established. Possible reasons include the sparseness and heterogeneity of available studies and, conceivably, the different impact the same genetic factors may have in different underlying renal diseases. Most studies evaluated the relationships between ACE I/D and adult polycystic kidney disease (APKD) or IgA nephropathy. These studies were recently reviewed in two comprehensive meta-analyses showing that this polymorphism is not associated with the progression of APKD (20) but may affect both the incidence and progression of IgA nephropathy, although to a different extent in different considered populations (21). Indeed, comparative analyses between 1339 patients with IgA and 1881 healthy controls found that the DD compared with the II and ID genotype was associated with a more than double incidence of IgA nephropathy in Asians, but with a similar risk of disease in whites. On the contrary, comparative analyses between 2706 progressors and 1578 nonprogressors found that the ACE I/D polymorphism remarkably affected the risk of ESKD in both populations, to the extent that Asian and white carriers of the DD genotype had, respectively, a 78% and 90% excess incidence of ESKD compared with carriers of the II or ID genotypes considered together (21).

A wide number of relatively small studies evaluated the influence of ACE I/D polymorphism on the risk of developing idiopathic nephrotic syndrome and eventually progressing to ESKD, but results were largely inconclusive and often contrasting (29–33). This conceivably reflected the limited power of the studies, the heterogeneity of considered populations and the confounding effect of concomitant treatments that, altogether, converged to increase the risk of random fluctuations of final data. One randomized, double-blind, placebo-controlled, clinical trial, the Ramipril Efficacy In Nephropathy (REIN) study (34), was formally designed to test whether glomerular protein traffic and its modulation by ACE inhibitor therapy influenced chronic renal disease progression. This study prospectively evaluated the relationships between ACE I/D polymorphism and kidney function loss by serial GFR measurements by gold-standard techniques in patients with different nondiabetic renal diseases (19). Data in 212 genotyped patients showed a similar rate of GFR decline and incidence of ESKD in different ACE I/D subgroups, an effect, however, that was the result of different response to ACE inhibitor and conventional therapy in considered groups. When the analyses were restricted to those on placebo, male patients with the II or ID genotypes were found to have a slower progression to ESKD than those with the DD genotype (35). Similar outcomes were described by a smaller study in 70 patients with moderately advanced renal insufficiency showing a slower progression in II or ID than in DD males (36), a trend that was observed also in females when the analyses were restricted to patients with baseline proteinuria <3.5 g/24 h. Along the same line, van Essen et al. found a slower progression in 64 patients with the ID or II genotype compared with 17 DD patients (37). Consistently, a retrospective analysis evaluating the prevalence of different genotypes in 260 ESKD patients and 327 controls found an association between the II and ID genotype and slower progression among patients with nondiabetic kidney disease (38).

Altogether, these data show a slower progression in patients with the II or ID genotype, a trend that appears to be particularly consistent in the male gender.

ACE I/D Polymorphism and Response to RAS Inhibitor Therapy

Nondiabetic Renal Disease

ACE Inhibitors. Data on the interactions between ACE I/D polymorphism and response to ACE inhibitor therapy are quite contrasting in type I and type II diabetics (Table 1). A large study in type I diabetes evaluated the interaction between ACE I/D polymorphism and ACE inhibitor therapy in 530
Table 1. Main studies evaluating the relationships between ACE I/D genotypes and response to ACE inhibitor therapy in diabetic renal disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Ethnicity</th>
<th>Type of diabetes</th>
<th>No. of patients</th>
<th>Follow-up (yr)</th>
<th>Patient characteristics</th>
<th>Treatment in genotype groups</th>
<th>Adjustments for relevant covariates</th>
<th>Effect of ACE inhibitor therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penno et al. (39), 1998</td>
<td>White</td>
<td>I</td>
<td>530</td>
<td>2</td>
<td>Normotension, normoalbuminuria (75%), or microalbuminuria (15%)</td>
<td>Comparable</td>
<td>Yes</td>
<td>Albuminuria reduction versus placebo: II, 51.3%; ID, 14.8%; DD, 7.7%</td>
</tr>
<tr>
<td>Jacobsen et al. (40), 2003</td>
<td>White</td>
<td>I</td>
<td>169</td>
<td>6</td>
<td>Persistent microalbuminuria</td>
<td>Comparable</td>
<td>Yes</td>
<td>Rate ratio of doubling serum creatinine or ESKD for each D allele: 1.81 (95% CI, 1.09-3.03)</td>
</tr>
<tr>
<td>Parving et al. (41), 1996</td>
<td>White</td>
<td>I</td>
<td>35</td>
<td>7</td>
<td>Macroalbuminuria</td>
<td>Comparable</td>
<td>Yes</td>
<td>More albuminuria reduction and slower GFR decline in II than ID + DD</td>
</tr>
<tr>
<td>Jacobsen et al. (42), 1998</td>
<td>White</td>
<td>I</td>
<td>60</td>
<td>0.5</td>
<td>Overt nephropathy</td>
<td>Comparable</td>
<td>Yes</td>
<td>More albuminuria reduction in II than ID or DD</td>
</tr>
<tr>
<td>So et al. (44), 2006</td>
<td>Asian</td>
<td>II</td>
<td>2089</td>
<td>3.7</td>
<td>Normoalbuminuria (58.6%), microalbuminuria (21.2%), or macroalbuminuria (20.2%)</td>
<td>Comparable</td>
<td>Partial</td>
<td>Hazard ratio for the renal composite endpoint: DD, 0.95; ID, 0.43; II, 0.52</td>
</tr>
<tr>
<td>Ha et al. (45), 2000</td>
<td>Asian</td>
<td>II</td>
<td>83</td>
<td>0.25</td>
<td>Overt nephropathy</td>
<td>Unbalanced albuminuria</td>
<td></td>
<td>Albuminuria reduction: DD, 52.6%; ID, 19.2%; II, 24.8%</td>
</tr>
</tbody>
</table>
patients with normoalbuminuria or microalbuminuria included in the EURODIAB Controlled Trial of Lisinopril in IDDM, a prospective, randomized, clinical trial aimed to compare the effects of 2 yr treatment with lisinopril or placebo on urinary albumin excretion rate (39). At study end, the ACE inhibitor compared with placebo reduced albuminuria by 51.3% in those with the II genotype, and by 14.8% or 7.7% in those with the ID or DD genotype, respectively. Finding that in the II group the difference was statistically significant, even after adjustment for gender and baseline and follow-up BP and metabolic control, provided consistent evidence that the I allele compared with the D allele was associated with a better antiproteinuric response to ACE inhibitor therapy.

Other studies in type I diabetes included patients with incipient or overt nephropathy. All patients were on ACE inhibitor therapy; thus, treatment effect could not be assessed versus placebo. However, comparative analyses between different genotypes consistently showed in the three studies that best outcomes were associated with the I allele. Among the 169 patients with overt nephropathy studied by Jacobsen et al. (40), the I allele was associated with a slower progression to doubling of serum creatinine or ESKD. This confirmed and extended previous evidence from two other albeit smaller studies. Parving et al. (41) showed that GFR decline over time was significantly slower in 24 patients who were heterozygous or homozygous for the I allele than in 11 patients homozygous for the D allele. Jacobsen et al. (42) showed more albuminuria reduction with captopril therapy in II than in ID or DD carriers. In all of the above studies, superior outcomes in the II groups were significant, even after adjustment for baseline characteristic and BP and metabolic control on follow-up, which can be taken to suggest that the I allele increases the responsiveness to the renoprotective effects of ACE inhibition therapy. A possible explanation is that ACE inhibitors reduce glomerular capillary hydraulic pressure more effectively in patients with the II than in those with the DD genotype (43). In II carriers, amelioration of glomerular hypertension might amplify the long-term protective effect of ACE inhibitor therapy against development and progression of nephropathy, in particular in those at increased risk because of poor metabolic control. Whether and to which extent the hemodynamic response to ACE inhibitor therapy depends on ACE plasma levels and/or ACE kidney activity, however, is still unknown. Regardless of the above, evidence that whites with the II genotype are protected from angiotensin II blockade. Whether this may apply also to ACE I/D Polymorphism in CKD 1515

In summary, within the limitation of the heterogeneity of the above data that were generated by studies that largely differed for the characteristics of included patients, severity of kidney disease, design and duration of follow-up, available data suggest that in both type I and type II diabetes early intervention with ACE inhibitor therapy may be particularly effective in patients with the I allele. This may have practical implications for healthcare providers in planning population-based screening and prevention strategies. At the stage of overt nephropathy, all patients without specific contraindications should be offered ACE inhibitor therapy regardless of the type of diabetes and the ACE I/D genotype.

Angiotensin II Receptor Antagonists. Two relatively small studies by Andersen et al. (46,47) found that the antiproteinuric effect of 30- and 4-mo ARA with losartan was substantially independent of the ACE I/D polymorphism in 54 hypertensive whites with type I diabetes and overt nephropathy (Table 2). Along the same line, Haneda et al. (48) found no associations between treatment-induced proteinuria reduction and I/D polymorphism in 126 Asians with type II diabetes and overt nephropathy. More robust data on the interactions between ACE I/D polymorphism and ARA therapy have been provided by prespecified analyses of the Reduction of Endpoints in NIDDM with the Antagonist Losartan study, a double-blind, multicenter, prospective, randomized, placebo-controlled clinical trial designed to evaluate the renal effects of losartan in 1513 type II diabetic patients with overt nephropathy (49). Data in the 1435 patients with available ACE I/D data (50) showed a risk reduction for ESKD of 3.1%, 30.5%, and 50.4% in the II, ID, and DD groups, respectively (Table 2). Consistently, the risk of progression to the composite endpoint (doubling of baseline serum creatinine, ESKD, or death) was decreased by 17.5% and by 38.1% in those with the II compared with those with the ID or DD genotype. Findings that differences in both outcomes were statistically significant between considered subgroups even after adjustments for main baseline and follow-up covariates provided convincing enough evidence that in overt nephropathy of type II diabetes the D compared with the I allele is associated with better response to angiotensin II blockade. Whether this may apply also to ACE
inhibition is unknown because no adequately powered randomized clinical trial evaluated so far the relationships between ACE I/D polymorphism and the protective effect against ESKD of ACE inhibitor therapy. Vis-à-vis comparative studies evaluating response to ACE inhibitor and angiotensin II blocker therapy in homogeneous patient populations are needed to establish which is the treatment of choice (if any) according to the type of diabetes and the stage of renal involvement.

Nondiabetic Renal Disease

ACE Inhibitors. Several studies evaluated the relationships between ACE I/D polymorphism and response to ACE inhibitor therapy, but many of them provided inconclusive or unreliable information because of the too small sample size or short follow-up (51–54). To address this issue, here we considered only those studies that included at least 30 patients who were followed for a minimum of 1 mo (Table 3). The largest study in whites satisfying these criteria considered 212 patients included in the REIN study and followed prospectively with serial GFR measurements for a median of 30 mo. Data showed that, independent of the underlying disease, ACE inhibition with ramipril compared with conventional, non-RAS inhibiting therapy consistently reduced proteinuria, the rate of GFR decline (ΔGFR), and incidence of ESKD in those with the DD genotype. A similar trend in proteinuria and, even if less consistent, in ΔGFR and events was observed also in patients with the ID genotype, whereas all considered outcomes were virtually identical on ramipril or conventional therapy among patients with the II genotype (Table 3). These different trends were not explained by differences in patient characteristics that were similar between different genotypes. Of note, finding that BP control was also similar between groups suggests that different outcomes reflected a specific effect of the ACE I/D polymorphism on intrinsic kidney responsiveness to ACE inhibitor therapy (19). Consistently, a smaller study in patients with IgA nephropathy found more treatment-induced proteinuria reduction in those with the DD than in those with the ID or II genotype (55). Other studies that, compared with the REIN analysis, included remarkably smaller numbers of patients, had shorter follow-up and, in most cases, did not measure the GFR failed to find a correlation between ACE I/D polymorphism and response to ACE inhibitor treatment (56,57) or even showed a better outcome on ACE inhibitor therapy in carriers of the I allele (37,58). In addition to the limited statistical power of the above studies, a possible interpretation for these findings is that in those with the DD genotype the response to ACE inhibitors was blunted by an excessive dietary intake of sodium (57). Indeed, evidence is available that response to ACE inhibitor therapy is more dependent on concomitant sodium intake in patients with the DD than in those with the ID or II genotype. A stronger gene-environment interaction in those with the DD genotype was originally described by van der Kleij et al. in healthy subjects receiving angiotensin I infusion in combination

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Andersen et al. (46), 2003</th>
<th>Andersen et al. (47), 2002</th>
<th>Parving et al. (50), 2008</th>
<th>Haneda et al. (48), 2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of diabetes</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>Asian</td>
</tr>
<tr>
<td>No. of patients</td>
<td>54</td>
<td>54</td>
<td>1435</td>
<td>126</td>
</tr>
<tr>
<td>Follow-up (yr)</td>
<td>3</td>
<td>0.33</td>
<td>3.4</td>
<td>0.25</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>Hypertension with persistent albuminuria</td>
<td>Comparable</td>
<td>Proteinuria</td>
<td>Proteinuria</td>
</tr>
<tr>
<td>Baseline characteristics of genotype groups</td>
<td>Comparable</td>
<td>Comparable</td>
<td>Comparable (but BMI and race)</td>
<td>Comparable</td>
</tr>
<tr>
<td>Treatment in genotype groups</td>
<td>Comparable</td>
<td>Comparable</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Adjustments for relevant covariates</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>?</td>
</tr>
<tr>
<td>Effect of ARA therapy</td>
<td>Comparable proteinuria reduction and GFR decline in II and DD</td>
<td>Comparable albuminuria reduction in II (55%) and DD (46%)</td>
<td>Risk reduction for ESKD: DD, 50.1%; ID, 30.5%; II, 3.1%</td>
<td>No interaction between genotype and albuminuria reduction</td>
</tr>
</tbody>
</table>

?, insufficient information.
Table 3. Main studies evaluating the relationships between ACE I/D genotypes and response to ACE inhibitor therapy in nondiabetic renal disease

<table>
<thead>
<tr>
<th>ethnicity</th>
<th>Ruggenenti et al. (35), 2000a</th>
<th>Perna et al. (19), 2000a</th>
<th>Essen et al. (37), 1996</th>
<th>van der Kleij et al. (56), 1997</th>
<th>van der Kleij et al. (57), 1997</th>
<th>Haas et al. (58), 1998</th>
<th>Yoshida et al. (55), 1995</th>
<th>Moriyama et al. (54), 1995</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>352</td>
<td>212</td>
<td>81</td>
<td>61</td>
<td>88</td>
<td>36</td>
<td>53</td>
<td>36</td>
</tr>
<tr>
<td>Follow-up (yr)</td>
<td>6</td>
<td>4.7</td>
<td>3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.5</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>Persistent proteinuria</td>
<td>Persistent proteinuria</td>
<td>Proteinuria</td>
<td>Stable proteinuria</td>
<td>Stable proteinuria</td>
<td>Protenuric glomerular disease</td>
<td>IgA nephropathy</td>
<td>Proteinuria</td>
</tr>
<tr>
<td>Baseline characteristics of genotype groups</td>
<td>Comparable</td>
<td>Comparable</td>
<td>Different GFR</td>
<td>Comparable</td>
<td>Comparable</td>
<td>?</td>
<td>Comparable</td>
<td>?</td>
</tr>
<tr>
<td>Treatment in genotype groups</td>
<td>Comparable</td>
<td>Comparable</td>
<td>Comparable</td>
<td>Comparable</td>
<td>Comparable</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Adjustments for relevant covariates</td>
<td>Yes</td>
<td>Yes</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>Yes</td>
<td>?</td>
</tr>
<tr>
<td>Effect of ACE inhibitor therapy</td>
<td>Slower ΔGFR and reduced ESKD in women and in DD men</td>
<td>Slower ΔGFR and reduced ESKD in DD, non significant effect in ID and II</td>
<td>Proteinuria reduction and slower ΔGFR in ID and II</td>
<td>Similar effects on proteinuria and GFR</td>
<td>Similar proteinuria reduction</td>
<td>Proteinuria reduction in ID and II</td>
<td>Proteinuria reduction in DD</td>
<td>More reduced proteinuria in ID + II versus DD</td>
</tr>
</tbody>
</table>

?, insufficient information.

aData retrieved from the Ramipril Efficacy in Nephropathy (REIN) trial.

bLess albuminuria reduction in DD with high sodium excretion.
with high or low sodium intake (59). Of interest, the response to angiotensin II was increased in patients with the DD compared with those with the ID or II genotype during high sodium intake, but no difference between the three ACE I/D genotypes was detectable when subjects were given a low sodium diet. Thus, a confounding effect of unrestricted sodium intake may explain why some studies failed to detect a superior renoprotective effect of ACE inhibitor therapy in DD than in ID or II patients with chronic renal disease (57). A possible confounding effect of gender must also be taken into consideration because, as demonstrated in the REIN study, the DD genotype remarkably increases the response to ACE inhibitors in males, whereas the role of ACE I/D polymorphism looks less consistent in females, that uniformly benefit of ACE inhibitor therapy regardless of their genotype (35).

Angiotensin Receptor Antagonists. Data on ARA treatment are limited to few and small studies (60–62), which does not allow drawing any conclusion on the impact of the ACE I/D polymorphism on response to angiotensin blockade (Table 4).

Altogether, and with the above limitations, available data can be taken to suggest that in diabetic and nondiabetic proteinuric renal disease the D allele is associated with an increased susceptibility to the protective effect of RAS inhibitor therapy against progression to ESKD. To formally test this hypothesis, we performed the meta-analysis described below.

Meta-analysis of Randomized Clinical Trials of RAS Inhibitor Therapy in Diabetic and Nondiabetic Proteinuric Renal Disease

Post hoc analyses of two large prospective, randomized, double blind, placebo-controlled clinical trials of RAS inhibitor therapy in diabetic (50) and nondiabetic (19) proteinuric renal disease reported data on progression to ESKD in DD, ID, or II genotypes considered separately. Both studies satisfied the Cochrane Collaboration criteria for the identification of randomized clinical trials and were considered in the present meta-analysis. ESKD was the primary outcome variable. Results (Figure 1) were expressed as ORs with 95% CIs. Sources of heterogeneity were quantified by I² statistics.

In the study group as a whole, the experimental treatment compared with placebo decreased the risk of progression to ESKD by 36% and the odds ratio was statistically significant (Figure 1). The effect of treatment, however, differed in different ACE I/D subgroups. In patients with the DD and ID genotype, RAS inhibition compared with placebo decreased the risk of ESKD by 68% and 23%, respectively, and the OR was statistically significant in both groups (Figure 1). On the contrary, no treatment effect was observed in the II subgroup. Of note, within each subgroup, patients with diabetic and nondiabetic proteinuric nephropathy showed a similar response to RAS inhibition, with a nonsignificant trend to more risk reduction in those with nondiabetic nephropathy within the DD subgroup.

A strength of this meta-analysis is that both considered studies were randomized, double-blinded and placebo-controlled. A major limitation is that the RAS was inhibited by an ARA in diabetic and by an ACE inhibitor in the nondiabetic population. Thus, it is impossible to establish whether the marginal differences in treatment effect within the DD genotype group are explained by the different underlying pathology (diabetic versus nondiabetic renal disease) or, alternatively, by the different treatment used to block the RAS. Regardless of the above, data consistently show that in both diabetic and nondiabetic proteinuric nephropathy the D allele is associated with a superior

<table>
<thead>
<tr>
<th>Table 4. Main studies evaluating the relationships between ACE I/D genotypes and response to ARA therapy in non diabetic renal disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnicity</td>
</tr>
<tr>
<td>No. of patients</td>
</tr>
<tr>
<td>Follow-up (yr)</td>
</tr>
<tr>
<td>Patient characteristics</td>
</tr>
<tr>
<td>Baseline characteristics of genotype groups</td>
</tr>
<tr>
<td>Treatment in genotype groups</td>
</tr>
<tr>
<td>Adjustments for relevant covariates</td>
</tr>
<tr>
<td>Effect of ACE inhibitor therapy</td>
</tr>
</tbody>
</table>

?, insufficient information.

aData retrieved from the English abstract.
protective effect of RAS inhibitor therapy against progression to ESKD. These findings may provide the background for prospective trials formally evaluating the effect of RAS inhibition therapy within patient populations a priori identified on the basis of their genotype. This approach could help address whether RAS inhibition is really poorly effective in patients with the II genotype and whether alternative treatments must be specifically investigated in this population.

Data from randomized trials considering microalbuminuria or macroalbuminuria as outcomes were not sufficient to definitely establish the interactions between ACE I/D polymorphism and RAS inhibition therapy.

Other RAS Polymorphisms and Their Interactions with the ACE I/D Polymorphism

Following the initial description of the I/D polymorphism of the ACE encoding gene, several gene polymorphisms for other components of the RAS, such as angiotensinogen (AGT) and the angiotensin II type I receptor (AT1R), have been reported, and over most recent years a progressively increasing number of studies tried to evaluate their biologic effects and their possible interactions with different ACE genotypes.

Angiotensinogen. More than 30 AGT genetic variants have been described so far (63,64) and one of them, a T to C base substitution at position 702 on exon 2 with consequent replacement of methionine 235 with threonine (M235T), has been associated with arterial hypertension (63), and with progression of diabetic nephropathy (65,66). Actually, the possibility that different AGT genotypes might result in different AGT bioavailability raised the intriguing hypothesis that RAS activity might be affected not only by ACE I/D genotypes but also by the several variants of the AGT gene. This boosted several studies that, however, failed to demonstrate any consistent relationship of considered AGT polymorphisms with RAS activity and cardiovascular or renal disease. Indeed, after the initial observation that the AGT M235T may be associated with higher AGT levels than the AGT M235M allele (63), subsequent studies showed that the AGT M235T polymorphism may account for no more than 5% of AGT variability (67). Moreover, in the only study showing a relationship between the T allele and increased angiotensin II plasma levels, the association could be detected only in male patients (68). This may explain why studies following the original report by Rogus et al. (66) failed to detect any significant association between AGT variants and diabetic (69–71) or nondiabetic (72,73) chronic kidney disease. Altogether, these data appear to challenge the hypothesis that AGT polymorphism may appreciably affect RAS activity and effects. Another explanation for the above inconsistent findings is that a more complex model than a single functional diallelic variant may explain AGT expression, which could

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>RAS therapy</th>
<th>Control therapy</th>
<th>Odds Ratio M-H, Random, 95% CI</th>
<th>Odds Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>1.1.1 DD polymorphism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parving 2008, ARA therapy</td>
<td>30</td>
<td>189</td>
<td>56</td>
<td>207</td>
</tr>
<tr>
<td>Perna A 2000, ACE therapy</td>
<td>6</td>
<td>36</td>
<td>29</td>
<td>9.9%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>225</td>
<td>236</td>
<td>33.3%</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>36</td>
<td>72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau^2 = 0.45; Chi^2 = 3.23, df = 1 (P = 0.07); I^2 = 69%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.02 (P = 0.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1.2 ID polymorphism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parving 2008, ARA therapy</td>
<td>67</td>
<td>352</td>
<td>84</td>
<td>317</td>
</tr>
<tr>
<td>Perna A 2000, ACE therapy</td>
<td>10</td>
<td>37</td>
<td>12</td>
<td>40</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>389</td>
<td>357</td>
<td>39.4%</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>77</td>
<td>96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.27, df = 1 (P = 0.60); I^2 = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.26 (P = 0.02)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1.3 II polymorphism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parving 2008, ARA therapy</td>
<td>39</td>
<td>170</td>
<td>42</td>
<td>200</td>
</tr>
<tr>
<td>Perna A 2000, ACE therapy</td>
<td>3</td>
<td>13</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>183</td>
<td>208</td>
<td>27.3%</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>42</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.04, df = 1 (P = 0.84); I^2 = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.41 (P = 0.68)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>797</td>
<td>801</td>
<td>100.0%</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>155</td>
<td>212</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau^2 = 0.14; Chi^2 = 11.61, df = 5 (P = 0.04); I^2 = 57%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.07 (P = 0.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Effects of RAS inhibitor therapy compared with placebo according to the DD, ID, or II genotype. A meta-analysis of two prospective, randomized, double-blind, placebo-controlled trials in patients with diabetic or nondiabetic proteinuric nephropathies.
be affected by different and still poorly understood combinations of several AGT gene variants.

**Angiotensin II Type 1 Receptor.** In 1994, Bonnardeaux et al. (74), analyzing the entire coding and 3’ untranslated regions of the ATIR encoding gene, identified five silent polymorphisms: T573C, A1062G, A1166C, G1517T, and A1878G. Whites with arterial hypertension (75,76) or type II diabetes (77) were subsequently found to carry the 1166C allele more frequently than healthy controls. The 1166C allele was also associated with an increased risk of microalbuminuria (70) and a faster progression of nephropathy (78) in patients with type II diabetes, findings that, however, were in contrast with data from other studies showing no association between the A1166C polymorphism and diabetic renal disease (79).

A case-control study in ESKD patients found an association between the A1166C and the progression of non-diabetic kidney disease (72). However, studies focusing on specific renal diseases, such as focal segmental glomerulosclerosis, IgA nephropathy, and APKD (33,73,80–83) failed to detect any association between this polymorphism and progression.

**Interactions with ACE I/D Polymorphism.** Marrè et al. found that in a large cohort of type I diabetics with proliferative retinopathy and different renal involvement (ranging from no evidence of renal disease to microalbuminuria, macroalbuminuria, or renal insufficiency), the severity of renal disease was associated with the D allele of the ACE I/D polymorphism and, among patients with the ID or DD genotypes, renal involvement increased from AGT MM to TT genotypes (84). They concluded that both polymorphisms are risk factors for the progression of glomerular disease in uncontrolled type 1 diabetic patients. Jacobsen et al. also found that the number of M(M235T)/D(I/D)/A(A1166C) alleles influenced albuminuria and time to doubling of serum creatinine or ESKD in 169 patients with type I diabetes (40). Along the same line, Bantis et al., described a synergistic association of AGT M235T and ACE I/D polymorphisms also with the progression of IgA nephropathy to ESKD (85) and found that those patients who carried more than two ACE-D or AGT-T alleles (that is the DD/TT, DD/MT, or ID/TT genotypes) were the ones with the largest benefit from ACE inhibitor therapy. In contrast with the above findings, however, Osawa et al. (86) failed to detect any significant association of ATIR A1166C, ACE I/D, and AGT M235T polymorphisms with diabetic renal disease. Thus, whether and to what extent the interactions between ATIR, and ATIR, and ACE polymorphisms may affect the progression of diabetic and nondiabetic chronic renal disease and response to RAS inhibitor therapy is still unclear.

**Other Non-RAS Polymorphisms and Their Interactions with the ACE I/D Polymorphism**

**Endothelial Nitric Oxide Synthase Polymorphism.** Nitric oxide generated through the endothelial nitric oxide synthase (eNOS) modulates vascular tone by contrasting the effects of several vasoconstrictors, inhibits smooth muscle cell proliferation, and prevents endothelial platelet adhesion, and its inhibition has been associated with increased BP and accelerated progression of kidney disease (87). After Wang et al. (88) described a 27-bp long repeat in the fourth intron of eNOS, the 4a/4b polymorphism, associated with the risk to develop coronary vascular disease in smokers, a progressively increasing number of studies tried to assess the biologic effects of this polymorphism and its possible interactions with the RAS. Again, results of genetic studies were contrasting, with some authors showing an association with the progression of IgA nephropathy (89) that was not confirmed by others (90). Of note, however, in a combined gene analysis of eNOS 4a/4b, ACE I/D, AGT M235T, and ATIR A166C polymorphisms in a large cohort of patients with idiopathic membranous nephropathy, Stratta et al. found that the combination of aa+ba of eNOS 4a/4b genotypes with II+ID ACE I/D or TT+MT AGT M235T genotypes was associated with accelerated renal disease progression, whereas the same eNOS polymorphism had no predictive role when considered alone (91). This finding suggests that in some circumstances a single gene variant may result in appreciable phenotypic changes only upon combination with other polymorphisms that may result in additional or synergistic effects on the same metabolic pathways.

**Alpha-adducin.** Studies in Milan hypertensive rats found that hypertension develops in this rat strain because of a primary increase in kidney sodium reabsorption because of a functional point mutation in the gene coding for α-adducin (ADD1) (92) (93) and a point mutation in the ADD1 coding region (G460W) was subsequently associated with hypertension also in humans (94). Pedrini et al. (95) found that risk for microalbuminuria was increased in patients with essential hypertension who were GG homozygous for the G460W polymorphism of ADD1. The association between hypertension and albuminuria, however, was significant only in DD carriers of the ACE I/D polymorphism. Consistently, Wang et al. (96) observed that, in 1454 subjects randomly selected from a white population, those with the combined presence of the W and D alleles of the ADD1 G460W and ACE I/D polymorphisms, respectively, were at increased risk of renal disease. The WW genotype was also associated with faster progression in Japanese patients with IgA nephropathy when combined with the II ACE genotype (97).

Thus, the above preliminary findings provide some evidence that polymorphisms of components of non-RAS pathways, in combination with different ACE I/D genotypes, may affect the risk of development and progression of chronic kidney disease.

**Strengths and Limitations**

The present review was focused on the relationships between ACE gene polymorphism, development and progression of chronic renal disease, and response to RAS inhibitor therapy. Data on possible interactions between the ACE I/D polymorphism and polymorphisms of genes encoding for other components of the RAS, such as angiotensinogen and angiotensin II type 1 receptor, were less extensively discussed. Actually, the review was not intended to consider the entire polymorphic spectra of RAS genes, such as tagging SNPs and/or haplotypes, also because of the limited information about their specific role in disease progression and response to treatment. The review considered only published studies that included at least 30
patients followed for at least 3 mo to limit the risk of confounding
data retrieved from studies that were too small or short to
reliably assess possible relationships between considered poly-
morphisms and disease outcome. The meta-analysis considered
only prospective, randomized, double blind, placebo-con-
trolled clinical trials that had a similar design and included
patients with homogeneous clinical conditions. This limited the
risk of bias associated with study heterogeneity. However, only
two trials satisfied these characteristics, which limits the gen-
eralizability of the findings. Moreover, no trial so far stratified
patients according to the DD, ID, or II genotype before random-
ization to RAS inhibitor therapy YES or NO. Availability of
trials with this design would certainly increase the power of
analyses aimed at evaluating the relationships between re-
sponse to RAS inhibition and ACE 1/D polymorphism. The
exclusion of unpublished studies cannot definitely rule out the
possibility of a selection bias, but this very unlikely affected the
results of the analysis to any appreciable extent. The analyses of
individual data were beyond the purposes of the present work.

Conclusion
Despite the huge amount of studies looking for candidate
genes, the ACE gene remains the unique, well-characterized
locus clearly associated with pathogenesis and progression of
chronic kidney disease. Thus, evaluating the ACE 1/D polymor-
phism is by no means a reliable and cost-effective tool to
identify patients at risk and those who may benefit the most of
renoprotective therapy with ACE inhibitors or angiotensin II
antagonists and, possibly, with other inhibitors of the RAS,
such as renin and aldosterone antagonists. In addition to guid-
ing pharmacologic therapy in individual patients, ACE 1/D
genotyping might help design clinical trials in progressive ne-
phropathies and optimize prevention and intervention strate-
gies at population levels, in particular in countries were re-
sources are extremely limited and 1 million patients continue to
die every year of cardiovascular or renal disease (98). Focusing
on patients who, on the basis of their ACE 1/D genotype, are
expected to have a higher rate of events and/or to have events
more effectively prevented by a given intervention, would
increase the power of analyses aimed to test the advantages of
novel, experimental treatments compared with conventional
therapy. This would allow detecting a given treatment effect
with a reduced number of patients or, alternatively, a smaller
effect with the same number of patients. The possibility to limit
the size of clinical studies will certainly have major practical
implications because, with the improvements in standard of
care, the incremental benefits of novel versus preexisting treat-
ments are progressively decreasing and demonstrating these
benefits in randomized clinical trials requires a number of
patients that is exponentially increasing over time. This already
precludes the possibility to realize these trials to most academic
institutions and, should this trend continue over time, costs for
these trials will soon become unaffordable even for the most
powerful and reach pharmaceutical companies. Thus, ACE 1/D
genotyping, in addition to improving the feasibility of renal
and cardiovascular trials, will hopefully offer the academy the
chance to regain its central role in an important area of medical
research. This approach would also increase the cost-effective-
ness of prevention and intervention strategies focusing on sub-
jects a priori predicted to benefit from ACE inhibitors, angio-
tensin blockers, aldosterone antagonists, or other inhibitors of
the RAS that will soon become available for clinical use such as
renin antagonists or inhibitors of aldosterone synthesis. On the
other hand, the identification of a substantial proportion of
subjects that might not benefit from drugs that interfere with
the RAS is expected to boost research for novel treatments
targeted at other metabolic pathways that may play a role in the
pathogenesis and progression of renal and cardiovascular dis-
ease. In this perspective, screening for the ACE 1/D polymor-
phism may be an efficient approach to optimize intervention in
subjects at increased risk because of diabetes, hypertension, or
familial predisposition. In those with proteinuric CKD, geno-
type-guided ACE inhibitor therapy, in addition to extend free-
don from ESKD, may save direct costs for renal replacement
therapy (99). Whether ACE 1/D genotyping may prove cost-
effective also at population level is worth investigating, at least
in some specific settings. In this regard, it is worth mentioning
that, in parallel with the progressively expiring of patents for
ACE inhibitors, costs for ACE inhibitor therapy are expected to
remarkably decrease in a few years, which should allow imple-
mentation of their intensified use in preventing programs, in
particular in less favorable settings (100). In this perspective,
the possibility that population-based ACE 1/D genotyping to
guide ACE inhibitor therapy might increase the efficiency of
screening and prevention programs implemented in develop-
ing countries, such as the ones by the Commission for the
Global Advancement of Nephrology of the International Soci-
ety of Nephrology (98) might warrant some consideration.
Hopefully, more complex pharmacogenomic approaches will
help to identify even more effective preventive and therapeutic
strategies for renal patients in the future.

Acknowledgments
Supported in part by a grant from EU (GENECURE, contract no.
037697 of FP6). The authors thank Dr. Marina Noris for helpful critical
appraisal of the manuscript, Ms. Manuela Passera for manuscript prep-
paration, and Ms. Valeria Miglioli for literature retrieval.

Disclosures
None

References
1. Tigerstedt R, Bergman P: Niere und Kreislauf. Skan Arch
Physiol 8: 223–271, 1898
2. Goldblatt H: Studies on experimental hypertension: I. The
production of persistent elevation of systolic blood pres-
3. Braun-Menendez E, Page JH: Suggested revision of no-
4. Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP: The
5. Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP: The
282, 1954
ace i/d polymorphism in ckd


